CSF3

(redirected from GCSF)
Also found in: Acronyms.

CSF3

A gene on chromosome 17q11.2-q12 that encodes colony stimulating factor 3 (granulocyte), a cytokine that controls the production, differentiation and function of granulocytes, the active protein product of which is located extracellularly.
References in periodicals archive ?
All instructions about the PRP and GCSF administration were given to all participants and following obtaining written consent, patients agreed to undergo intrauterine infusion of PRP or systemic administration of GCSF.
Granulocyte colony-stimulating factor (GCSF) accelerates reendothelialization and reduces neointimal formation after vascular injury in mice.
Prophylactic GCSF was given for 5 days to those patients who received chemotherapies with more than 20% risk of FN or dose dense schedules.
GCSF stimulates the neutrophilic granulocyte proliferation and is effective on the embryo implantation through decidual cells macrophage activation.
Ramirez et al., "Bone marrow cell mobilization by the systemic use of granulocyte colony-stimulating factor (GCSF) improves wound bed preparation," International Journal of Lower Extremity Wounds, vol.
[13] Chemotherapy and The side effects of placebo/chemotherapy and chemotherapy; use of CHM GCSF (d); safety evaluation UICC; the Sun [14] Chemotherapy/ side effects of chemotherapy and CHM chemotherapy (the WHO criteria); KPS score The side effects of Wu [15] Chemotherapy/ chemotherapy (the WHO chemotherapy and CHM criteria); immune function UICC; the side effects Xu et al.
Mobilized hematopoietic cells in peripheral blood were elevated after recombinant GCSF treatment, proving effects of treatment.
[16.] Basu S, Hodgson G, Katz M, Dunn AR (2002) Evaluation of role of GCSF in the production, survival, and release of neutrophils from bone marrow into circulation.
Pfizer also plans to employ its commercial capabilities, global scale, and scientific and development capabilities to significantly expand Hospira's portfolio of marketed biosimilars, including Retacrit to treat anemia associated with chemotherapy, and Nivestim, a biosimilar version of filgrastim (GCSF), to treat neutropenia.
RENEW was designed to determine the effectiveness of granulocyte-colony stimulating factor (GCSF) mobilized CD34+ stem cells (CD34+) to treat RA patients.
It is notable that 30% received prophylactic granulocyte colony-stimulating factor (GCSF) to reduce the risk of severe and/or febrile neutropenia, something which was not done in the pivotal TROPIC8 trial.
Microglial survival is governed by two key molecules: granulocyte colony stimulating factor (GCSF) and macrophage-colony stimulating factor-1 (MCSF-1).